Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Nov 21, 2024; 30(43): 4609-4619
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4609
Figure 6
Figure 6 Frequency distributions of plasma SHOX2, RNF180, SEPTIN9, and EPO methylation before and after therapy in patients with esophageal cancer (n = 23). Frequency distributions of plasma SHOX2, RNF180, SEPTIN9, and EPO methylation were less after therapy than before therapy.